Initiation of Insulin Aspart in Type 2 Diabetes

• Status: Completed
• Trial end date: 2004-02-02
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The aim of this trial is to investigate if using insulin aspart as start therapy will improve the efficacy on daytime blood glucose cycle profile in subjects with type 2 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type 2 diabetes for at least 3 years

• HbA1c greater than 8.0%

• Body Mass Index (BMI) below 40.0 kg/m2

• Inadequate treatment with diet and OADs

• Never received treatment with insulin

Exclusion Criteria:

• Type 1 diabetes

• Known or suspected allergy to investigational product